Oppenheimer analyst Hartaj Singh maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and maintains $500 price target.
Oppenheimer Maintains Outperform on Vertex Pharmaceuticals, Maintains $500 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.